Ann: Phase 1 CF33 VAXINIA Study Update - Positive Early Signals, page-277

Quite funny neu getting mentioned so much on here now. But I guess aligning us with winners is always good.

imu's path so far has been quite smooth compared to neu. Neu would be a great investor research project!

I remember when their sp crashed from 60c to 1.3c ($12 to 26c in current prices) after a phase 3 fail.

Then there was NNZ2256 for TBI, that failed the clinical trial (because the drug was flushing through the body we think). The tweaking of the clinical outcomes for the Trof trials, Richard Treagus leaving, investor disappointment in their deal (or deal partner).

Yet despite all this neu is now very successful, cash rolling in and good trial results.

So yes, things can certainly change.

However imu just keep on progressing imho, at least in the clinical trials. Looking forward to the higher dose results from the cf33 stable.

cheers

ps. For those who berate imu and their cap raisings, I think neu's last one was around a dollar, and just before a value inflection point.